EU/3/09/659

Table of contents

About

On 24 July 2009, orphan designation (EU/3/09/659) was granted by the European Commission to Chroma Therapeutics Ltd, United Kingdom, for tosedostat for the treatment of acute myeloid leukaemia.

The sponsorship was transferred to Voisin Consulting S.A.R.L., France, in May 2015.

For a list of the administrative updates to this public summary of opinion please refer to the PDF document below.

Please note that this product was withdrawn from the Community Register of designated Orphan Medicinal Products in March 2019 on request of the Sponsor.

Key facts

Active substance
tosedostat
Disease / condition
Treatment of acute myeloid leukaemia
Date of decision
24/07/2009
Outcome
Withdrawn
Orphan decision number
EU/3/09/659

Sponsor's contact details

Voisin Consulting S.A.R.L.
64 Avenue Pierre Grenier
92100 Boulogne-Billancourt
France
Tel. +33 1413 18300
E-mail: orphan@voisinconsulting.com

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating